Gene Therapy – Access to Innovative Therapies for Rare and Ultrarare Disorders

Women in Government Leadership & Innovation Summit

November 15, 2024





ultragenyX

Introductions







Rep. Donna White State of North Carolina NC Life Sciences Caucus Co-Chair

Moderator

Steven Gray, PhD University of Texas Southwestern Medical Center Director, Gene Therapy Program Professor, Dept. of Pediatrics

Gene Therapy 101

Josh Argall Devin's Father WI Rare Board Member Patient Advocacy Strategies VP, Engagement & Operations

Patient and Family Perspectives Erin Frey Ultragenyx Senior Director State Government Affairs

State Policy Considerations



What is Gene Therapy? Gene Therapy 101

8-8 1 1 1 1 1



UTSouthwestern Medical Center

Gene Therapy: Emerging Transformative Paradigms for Treatment of Human Disease

Steven Gray, Ph.D.


Professor of Pediatrics, Molecular Biology, and Neurology

Eugene McDermott Center for Human Growth & Development

Director, UT Southwestern Viral Vector Facility

Director, UT Southwestern Gene Therapy Program

Any stated opinions are Dr. Gray's own, and not necessarily representing UTSW.








The Way We Treat Cancer Will Be Revolutionized as Gene Therapy Comes to the U.S.

"Rare" Genetic Disease – a large but hidden problem



⁶ Source: EveryLife Foundation, published Feb 25, 2021

UT Southwestern Medical Center

Broken Genes Lead to Broken Proteins

Humans are made of cells that contain our **genes**



Genes are instructions for proteins




Proteins help cells function in a healthy manner





Abnormalities in genes can result in proteins that do not function properly



The promise of **gene therapy** is to fix a genetic disease at the source.

If you fix the DNA, you've solved the problem permanently.



How Does Gene Therapy Work?



Identify the causal defective gene



Package a *working* copy of the gene into a carrier like an engineered virus


Deliver the working copy of the gene back into the patient



Gene Therapy: Treating Patients


In Vivo Approaches

- Intervene inside the body
- Genome modifications within target cells after individuals receive a genomic medicine
- e.g., surgery, injection



Ex Vivo Approaches

Outside the body, create cell medicines by:



AAV Gene Therapy for AADC Deficiency



<u>Sci Transl Med.</u> 2012 May 16;4(134):134ra61.

Gene therapy for aromatic L-amino acid decarboxylase deficiency.

Hwu WL, Muramatsu S, Tseng SH, Tzen KY, Lee NC, Chien YH, Snyder RO, Byrne BJ, Tai CH, Wu RM.

Krabbe Disease

Affects ~1:100,000 children

Symptoms start at ~6 months

Typically fatal by 1-3 years old.




Jim and Jill Kelly with their son Hunter in 2004. Hunter, who had Krabbe disease, died in 2005 at age 8.

Don Heupel/AP

https://www.npr.org/sections/health-shots/2013/12/18/255226663/screening-newborns-for-disease-can-leave-families-in-limbo

Treatment of Dogs With Krabbe Disease



Bradbury et al, Journal of Clin Inv, 2020






Patients that deserve a better future



Exciting gene therapy technologies

Why aren't these two things coming together more?

Not enough patients for pharma involvement



Regulating Genomic Medicine

Center for Biologics Evaluation and Research



Food & Drug Administration



National Institutes of Health

- Regulation of gene & cell therapies are governed by the U.S. Department of Health & Human Services HHS (FDA & NIH)
- FDA treats all genome edited cells as medical products
- Federal law prohibits the FDA from reviewing INDs using human germline cells and prohibits the NIH from funding research in germline cells
- FDA prohibits the conduct of clinical trials using germline editing

Regulating Gene & Cell Therapy Products

Center for Biologics Evaluation and Research



Food & Drug Administration

- FDA has an established regulatory framework to regulate cell and gene therapy products
- FDA has recently developed new regulatory programs to help expedite review of cell and gene therapy products:
 - INTERACT
 - RMAT
- Cell and gene therapy products must fulfill the same evidentiary standards to prove safety and efficacy as any other FDA-approved drug

Sources:

FDA. Human Gene Therapy for Rare Diseases: Draft Guidance for Industry. July 2018.

FDA. Testing of Retroviral Vector-Based Human Gene Therapy Products for Replication Competent Retrovirus During Product Manufacture and Patient Follow-up; Draft Guidance for Industry. July 2018

FDA. Long Term Follow-up After Administration of Human Gene Therapy Products; Draft Guidance for Industry. July 2018.

Thank You





Josh's kids: Benny Devin Genevieve



State Policy Considerations



A Few Words on Pricing: Cost Conscious, Patient-Centered, Worldwide Access

Elements that impact gene therapy pricing

- Clinical
 - Clinical trial designs and endpoints
 - Small populations
 - Probability of success
- Manufacturing practices
 - In-house or outsource
 - Cost of goods
- Improved science/processes over time.
- Pricing for majority access vs. other approaches.
- Value to patients and their caregivers/families.

Ultragenyx Gene Therapy Manufacturing Facility



State Policy that impacts the Rare Disease Community



Economic Development

- Focus on inviting life science, biotech and medical innovation companies into your state.
- Incentivize innovation with R&D tax credits



Earlier Diagnosis

- Newborn screening parity with the Recommended Uniform Screening Panel
- Rapid Whole Genome Sequencing Coverage
- Biomarker Testing Coverage

Access to Treatments



- Copay Accumulator Ban
- Prior Authorization reform
- Ensure any legislation appropriately recognizes rare disease
- Ensure Medicaid adds utilization criteria for new treatments swiftly



- Rare Disease Advisory Council
- Form a Rare Disease Caucus
- Ensure Medicaid includes rare experts and patient advocates in the Drug Utilization Review and Prescriptions & Therapeutics boards



Questions?

Panelists' Contact Information:

Steven Gray, PhD, <u>steven.gray@utsouthwestern.edu</u> Josh Argall, josh@patientadvocacystrategies.com Erin Frey, <u>efrey@ultragenyx.com</u>

